What are the latest clinical trials for Thyroid Cancer in 2026

Latest Clinical Trials for Thyroid Cancer in 2026

I appreciate your question about current thyroid cancer trials. However, I need to be transparent with you: the medical guidelines and resources I have access to are current through early 2025, and I don't have comprehensive data on all newly launched trials specifically for 2026.

That said, I can share what the most recent NCCN Guidelines (Version 1.2025) indicate about the treatment landscape and emerging approaches that are likely driving current and upcoming trials:

Active Treatment Areas in Thyroid Cancer Research

1. Targeted Therapies for Specific Mutations

According to NCCN Guidelines, molecular testing has become increasingly important for treatment decisions. Current trials are focusing on:

• RET-altered thyroid cancers: Selpercatinib (LOXO-292) has shown strong results and is FDA-approved for RET-mutant medullary thyroid cancer
• NTRK fusion-positive cancers: Larotrectinib and entrectinib are being studied for patients with these specific genetic changes
• BRAF V600-mutant anaplastic thyroid cancer: Dabrafenib and trametinib combinations are being investigated

2. Radioiodine-Refractory Differentiated Thyroid Cancer

The NCCN Guidelines highlight several FDA-approved options now being studied in combination:

• Lenvatinib (a multi-kinase inhibitor) - shown to improve progression-free survival
• Cabozantinib - approved for advanced thyroid cancer and being tested in combination approaches
• Sorafenib - another tyrosine kinase inhibitor for advanced disease

3. Immunotherapy Combinations

Recent NCCN data shows emerging interest in:

• Pembrolizumab combined with lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer
• Studies examining tumor mutational burden (TMB) as a predictor of immunotherapy response

4. Anaplastic Thyroid Cancer (Most Aggressive Type)

The NCCN Guidelines note active research in:

• Combination targeted therapy plus immunotherapy approaches
• Lenvatinib/pembrolizumab combinations showing promise in metastatic anaplastic thyroid cancer

How to Find Current 2026 Trials

For the most up-to-date information on active trials launching in 2026, I recommend:

1. ClinicalTrials.gov (clinicaltrials.gov)

   • Search: "thyroid cancer" + your specific type
   • Filter by: Status = "Recruiting" and Location = your area
   • Updated daily with new trials

2. NCCN Cancer Centers (nccn.org)

   • Many major cancer centers list their active thyroid cancer trials
   • Often have dedicated thyroid cancer research programs

3. ThyCa: Thyroid Cancer Survivors' Association (thyca.org)

   • Patient-focused resource with trial information
   • Excellent educational materials about treatment options

4. Your Oncology Team

   • They have access to trials matching your specific diagnosis, stage, and biomarkers
   • Can discuss which trials might be appropriate for your situation

Questions to Ask Your Healthcare Team About Trials

If you're considering a clinical trial, these questions can help guide your discussion:

1. "Are there any active trials for my specific type of thyroid cancer (papillary, follicular, medullary, or anaplastic)?"

2. "Have my tumor biomarkers (RET, BRAF, NTRK, etc.) been tested? Are there targeted therapy trials available based on my results?"

3. "What is the trial comparing my treatment to—is it a new drug versus standard treatment or placebo?"

4. "What are the potential side effects, and how are they monitored?"

5. "If the trial drug isn't working for me, can I switch to another treatment?"

6. "Will the trial be covered by my insurance, or does the sponsor cover costs?"

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions about clinical trial participation.